Imiquad Cream: Clinically Proven Topical Immunotherapy for Skin Conditions
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per sachet | Price | Buy |
| 12 | $5.02 | $60.24 (0%) | 🛒 Add to cart |
| 24 | $3.35 | $120.48 $80.32 (33%) | 🛒 Add to cart |
| 36 | $3.07 | $180.72 $110.44 (39%) | 🛒 Add to cart |
| 60 | $2.84 | $301.20 $170.68 (43%) | 🛒 Add to cart |
| 96 | $2.61
Best per sachet | $481.93 $251.00 (48%) | 🛒 Add to cart |
Similar products
Imiquad Cream is a prescription topical immunomodulator indicated for the treatment of external genital and perianal warts/condylomata acuminata in adults, superficial basal cell carcinoma, and actinic keratosis. Its active ingredient, imiquimod, works by stimulating the local immune response, enabling the body to target and eliminate abnormal cells. This cream represents a significant advancement in dermatological therapeutics, offering a non-invasive treatment option with demonstrated efficacy across multiple dermatologic indications. Proper application and medical supervision are essential to achieve optimal therapeutic outcomes while minimizing potential adverse effects.
Features
- Contains 5% imiquimod as the active pharmaceutical ingredient
- Available in single-use packets or multi-use tubes (250mg and 500mg sizes)
- White-to-light-yellow oil-in-water emulsion cream formulation
- pH maintained between 6.0–7.5 for skin compatibility
- Preservative system includes benzyl alcohol and methylparaben
- Storage requirement: 2°C–25°C (36°F–77°F)
Benefits
- Stimulates localized immune-mediated clearance of viral warts and precancerous lesions
- Provides non-invasive treatment alternative to surgical procedures
- Demonstrates high clearance rates with reduced recurrence compared to destructive therapies
- Enables patient-administered treatment with proper medical guidance
- Offers targeted action with minimal systemic absorption
- Shows dual antiviral and antitumor activity through cytokine induction
Common use
Imiquad Cream is primarily prescribed for three dermatological indications. For external genital and perianal warts, it is applied to visible lesions in immunocompetent adults. In superficial basal cell carcinoma, it is used for histologically confirmed lesions measuring ≤2.0 cm in diameter on the trunk, neck, or extremities (excluding hands and feet), particularly when surgical methods are less appropriate. For actinic keratosis, it is applied to clinically typical, non-hyperkeratotic, non-hypertrophic lesions on the face or scalp in immunocompetent adults. Treatment duration and frequency vary by indication, typically ranging from 3-16 weeks depending on clinical response and tolerability.
Dosage and direction
Genital Warts: Apply a thin layer to affected area 3 times per week (e.g., Monday, Wednesday, Friday) prior to normal sleeping hours. Leave on skin for 6-10 hours, then wash off with mild soap and water. Treatment continues until complete clearance or maximum 16 weeks.
Superficial Basal Cell Carcinoma: Apply 5 times per week for 6 weeks. Apply prior to bedtime, leave on for approximately 8 hours, then wash area thoroughly.
Actinic Keratosis: Apply 2 times per week for 16 weeks. Apply prior to bedtime, leave on for approximately 8 hours, then wash area.
Use sufficient cream to cover treatment area, but not exceeding packet contents (single-use packets contain 250mg cream). Wash hands before and after application. Avoid occlusive dressings unless directed by physician.
Precautions
- For external use only; avoid contact with eyes, lips, and nostrils
- Not for oral, intravaginal, or intra-anal use
- Sexual contact should be avoided while cream is on skin
- May weaken condoms and diaphragms; avoid contact during treatment
- Use with caution in patients with autoimmune disorders or those taking immunosuppressive therapy
- Monitor for excessive skin reactions; treatment interruption may be necessary
- Sun exposure should be minimized during treatment period
- Not recommended for use in children under 12 years
- Use during pregnancy only if potential benefit justifies potential risk
- Nursing mothers should avoid application to breast area
Contraindications
- Hypersensitivity to imiquimod or any component of the formulation
- Patients with congenital or acquired immunodeficiencies
- Application on open wounds or broken skin
- Use on mucosal membranes (except external genital/perianal areas as indicated)
- Concurrent use with other topical medications on same treatment area
- Patients with unrealistic treatment expectations or inability to follow directions
Possible side effect
Very common (>10%): Local skin reactions including erythema, edema, itching, burning, tenderness, flaking/scaling, erosion/ulceration, scabbing/crusting. Application site pain. Headache.
Common (1-10%): Fatigue, fever, malaise, influenza-like symptoms. Nausea. Back pain. Myalgia. Fungal infections. Lymph node enlargement near treatment area.
Uncommon (0.1-1%): Skin discoloration, rash, herpes simplex reactivation. Diarrhea. Dizziness.
Rare (<0.1%): Severe skin reactions, autoimmune disorders exacerbation. Alopecia at application site. Eye disorders if accidental contact occurs.
Most local reactions peak during weeks 2-3 of treatment and gradually resolve after therapy completion. Systemic reactions are generally mild to moderate and self-limiting.
Drug interaction
Formal drug interaction studies have not been conducted. However:
- Concomitant use with other topical products may increase skin irritation
- Immunosuppressive agents may reduce efficacy
- Avoid concurrent use with corticosteroids on same treatment area
- No known interactions with systemic medications, but caution advised with drugs affecting immune function
- Theoretical potential for interaction with live vaccines; consult physician before vaccination during treatment
Missed dose
Apply missed dose as soon as remembered, unless it is almost time for next application. Do not apply double dose to make up for missed application. Resume regular application schedule. If several doses are missed, consult healthcare provider for guidance on treatment continuation.
Overdose
Topical overdose may result in severe local skin reactions including intense erythema, edema, and erosion. Systemic overdose is unlikely due to minimal absorption. If accidental ingestion occurs, gastric lavage and symptomatic treatment may be considered. For topical overdose, wash area thoroughly with water and mild soap. Seek medical attention if severe reactions occur. Supportive care should be provided based on symptoms.
Storage
Store at 2°C–25°C (36°F–77°F). Do not freeze. Keep in original container, tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any remaining cream 30 days after opening multi-use tube.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Individual results may vary. Proper diagnosis and supervision by a physician are essential before using Imiquad Cream. The manufacturer is not liable for improper use or self-diagnosis. Full prescribing information should be reviewed before initiation of therapy.
Reviews
Clinical studies demonstrate complete clearance rates of 50-85% for genital warts, with recurrence rates of 5-20% over follow-up periods. For superficial basal cell carcinoma, histologic clearance rates of 82-100% have been reported. In actinic keratosis, complete clearance rates of 45-57% were observed. Most patients experience local skin reactions indicating immune activation, with severe reactions requiring treatment interruption in approximately 2-4% of cases. Patient satisfaction surveys indicate preference for non-invasive treatment despite frequent local reactions. Long-term follow-up studies show sustained efficacy with proper application technique and medical supervision.